List of Ongoing Diabetes-related Trials That Are Actively Recruiting Patients
| Stanford Precision Health ADVANCE Biobank | Who We Are - Our Vision The Stanford Precision Health Biobank is a hospital-wide initiative, leading the way in biomedical revolution through investigation of the role of inherited genetic information in the risk of developing human diseases. We are committed to providing innovative resources that not only protect the integrity of biological samples but also unlock their potential for ground breaking discovery. The dynamic environment of interdisciplinary exploration and collaboration at Stanford School of Medicine campus and beyond in the Bay Area, empowers us to seize unprecedented opportunities to advance human health. This study will focus on creating the largest biobank of blood samples collected from individuals of Asian descent, with or without the diagnosis of Type 1 or Type 2 Diabetes. Goal Of This Study The goal of this study is to learn how our genes affect the risk of getting diseases, how well certain treatments might work, and if some treatments could be harmful. We want to see how differences in genes relate to your medical history. Who Can Participate? We are seeking participants from Asian American communities with or without the diagnosis of Type 1 or Type 2 Diabetes. Individuals of all ages are welcome to join our study. What Is Involved? -You will provide a blood sample at a Stanford location in Palo Alto -Your DNA will be analyzed for inherited traits. -Only approved researchers will access your genetic and medical information, which will be kept confidential and secure. How To Sign Up Read and sign the consent form for the Stanford Precision Health Biobank project by going to this URL: https://redcap.link/PrecisionHealthBiobank After completing the consent, you will be prompted to complete a short survey. Study Participation Participation is entirely voluntary. Upon enrollment, we will contact you to schedule a one-time blood draw, which is expected to take approximately one hour. FREQUENTLY ASKED QUESTIONS What happens to my samples? Once collected, your samples will be processed and stored for analysis using advanced mass spectrometry techniques to detect thousands of molecules. Individual results will not be available for several years, as our project is still in its early stages. Your treating physician will be notified only if a clinically significant result is identified, and only if you consented to receive such notifications. Is there a cost for participating? There is no cost to you for participating. Your health insurance will not be billed. You will receive $20 to cover transportation costs. CONTACT US Stanford Precision Health Biobank Contact: Oshra Sedan, osedan@stanford.edu Mailing Address: 1050 Arastradero Rd., Building A Palo Alto, CA 94304 Participant's rights questions: contact 1-866-680-2906 For more information, click here . |
| Normal Weight Diabetes Research Study |
We are currently looking for pre-diabetic or diabetic volunteers to determine whether dysfunctional fat and insulin resistance contribute to normal-weight diabetes. Participants have the opportunity to take pioglitazone and/or low-dose tirzepatide which reduce visceral/liver fat and improve insulin resistance with little or no weight loss. Participants can learn about their personalized insulin sensivity and insulin secretion, fat distribution and compositiion, fat cell function, and overall metabolic health. We are also looking for healthy volunteers to participate in our investigative study. To learn more about this study, follow the QR code in the flyer or contact Evelyn Yandle at eyandle@stanford.edu.
Please view healthy volunteer flyer here. Please view pre-diabetic or diabetic volunteer flyer here. |
| Person-Oriented Precision Screening (POPS) | The POPS study is designed to identify diabetes health risks and diabetes device distress among individuals living with type 1 diabetes or type 2 diabetes managed with daily insulin. Our goal is to support more personalized and effective diabetes management and care. Participation starts with a brief screening form to determine eligibility. Those who are eligible will be invited to complete a 30-minute online survey. Once finished, participants will receive personalized results based on their responses. Here is a list of our eligibility criteria:
Eligibility Criteria includes: * Type 1 or Type 2 diabetes and taking insulin daily * Age 18 or older * Proficient in English * Currently residing in the U.S. * Not currently pregnant * Internet access For more information, click here. |
| Better Breaks Study | Do you sit all day at work? Let’s fix that! Join a Stanford study to help you take more active breaks throughout your day.
You will take part in an eight-week physical activity intervention! You will be asked to either perform progressive strength
training exercises or take walking breaks throughout the day. As part of this study, you will receive two different reports of
how your body is managing glucose, or blood sugar. This study is looking to see how different types of breaks during the day can
help people improve their blood sugar control. We are currently focusing on recruiting those who are not taking insulin and those
who do not regularly exercise or do physical activity guidelines outside of work. This wave of the study is looking for those with high HBA1C levels- prediabetes range of 5.7-6.4 or 6.5 and above with diabetes currently controlling sugar with lifestyle choices only (not insulin).
For more information, click here. Any questions? Emails us at betterbreaks@stanford.edu. |
| For Pediatric Endocrinology studies, please see: | https://med.stanford.edu/pedsendo/research.html |
| DESIGNATE |
Information: -Ages 8 – 45 -Eligibility – T1D -New Onset within 18 months of diagnosis -30 adult participants must be enrolled and assessed prior to enrollment of pediatric subjects -Study Duration – 12 months -The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new onset T1DM. The secondary objectives are to: 1. Assess the safety profile of siplizumab in recently diagnosed T1DM. 2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants. Please contact Trudy Esrey at tesrey@stanford.edu for more information. |
| Diabetes Wellness Teen Study | The Diabetes Wellness Teen Study is investigating risk factors that predict future onset of
eating disorders in adolescents with type 1 diabetes. If you are between the ages of 11-17,
have type 1 diabetes, and use a continuous glucose monitor you may be eligible to participate!
You could earn up to $125. All study activities are completely virtual! If interested, use the link below and a member of the research team will reach out to you with more information! https://redcap.link/DWTSinterest Learn more: https://stanforddwts.weebly.com/ shirazh@stanford.edu 650-272-0461 For complaints, concerns, or participant's rights, contact 1-866-680-2906. |
| DREAM | DREAM is a study to find out how frequently people with acute pancreatitis develop diabetes.
High blood sugar (blood glucose) is a known complication of acute pancreatitis. Sometimes high
blood sugars can last a few weeks after acute pancreatitis and get better. However, sometimes high
blood sugars may not improve after acute pancreatitis and diabetes is diagnosed. Diabetes can also appear later,
a year or more after acute pancreatitis. Little data is available on how often or why diabetes occurs after acute pancreatitis.
The DREAM study will help to better understand diabetes after acute pancreatitis and who is at increased risk of developing it,
as well as the different types of diabetes that develop after acute pancreatitis.
For more information, please contact: Andrea Leung Email: aleung13@stanford.edu Phone : 650-725-3370 Naya Lee Email: nayaslee@stanford.edu Phone : 650-736-7680 |
